Edwards Lifesciences Corporation
EW
Rang in aandelen
#489
Edwards Lifesciences Corporation is a global medical technology firm... Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Aandeelprijs
$86.46
Laatst gesynchroniseerd: 2026-10-16
Marktkapitalisatie
$49.82B
Verandering (1 dag)
-1.75%
Verandering (1 jaar)
15.84%
Land
US
Handel Edwards Lifesciences Corporation (EW)
Categorie
Healthcare
EPS voor Edwards Lifesciences Corporation (EW)
EPS per June 2026 TTM: $1.74
Volgens de laatste financiële rapporten en de aandelenkoers van Edwards Lifesciences Corporation is de huidige EPS van het bedrijf (TTM) $1.74. Eind 2024 had het bedrijf een EPS van $6.98, een stijging ten opzichte van de EPS van 2023 die $2.31 bedroeg.
EPS-geschiedenis van Edwards Lifesciences Corporation van 2000 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $1.74 | -5.43% |
| 2025 | $1.84 | -73.64% |
| 2024 | $6.98 | 202.16% |
| 2023 | $2.31 | -6.10% |
| 2022 | $2.46 | 2.07% |
| 2021 | $2.41 | 82.58% |
| 2020 | $1.32 | -21.43% |
| 2019 | $1.68 | 46.09% |
| 2018 | $1.15 | 17.35% |
| 2017 | $0.98 | 10.11% |
| 2016 | $0.89 | 15.58% |
| 2015 | $0.77 | -39.37% |
| 2014 | $1.27 | 115.25% |
| 2013 | $0.59 | 37.21% |
| 2012 | $0.43 | 22.86% |
| 2011 | $0.35 | 9.37% |
| 2010 | $0.32 | -5.88% |
| 2009 | $0.34 | 78.95% |
| 2008 | $0.19 | 18.75% |
| 2007 | $0.16 | -15.79% |
| 2006 | $0.19 | 72.73% |
| 2005 | $0.11 | 4,300.00% |
| 2004 | 0.00 | -97.73% |
| 2003 | $0.11 | 40.49% |
| 2002 | $0.08 | -560.59% |
| 2001 | $-0.02 | -95.64% |
| 2000 | $-0.39 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $3.11 | 78.74% |
US
|
|
| $3.59 | 106.32% |
IE
|
|
| $9.73 | 459.20% |
US
|
|
| $2.48 | 42.53% |
US
|
|
| - | - |
DE
|
